What Heidi Overton's FDA Nomination Could Mean for Pharmacy

President Donald Trump's nomination of Heidi Overton, MD, PhD, to lead the FDA sets up a confirmation fight whose outcome could touch nearly every corner of the pharmacy—from how mifepristone is dispensed to whether childhood vaccines arrive as combination shots or individual doses. For pharmacists, the more consequential story is not the nomination itself but what an Overton-led FDA would mean at the counter, the point at which agency policy becomes a dispensing decision.^1,2